The Enterprise Value as of September 2024 (TTM) for Vaxcyte, Inc. (PCVX) is 11.96B

According to Vaxcyte, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 11.96B. This represents a change of 86.37% compared to the average of 6.42B of the last 4 quarters.

Vaxcyte, Inc. (PCVX) Historical Enterprise Value (quarterly & annually)

How has PCVX Enterprise Value performed in the past?

The mean historical Enterprise Value of Vaxcyte, Inc. over the last ten years is 1.72B. The current 11.96B Enterprise Value has changed 69.29% with respect to the historical average. Over the past ten years (40 quarters), PCVX's Enterprise Value was at its highest in in the June 2024 quarter at 8.53B. The Enterprise Value was at its lowest in in the June 2020 quarter at -36928577.42.

Vaxcyte, Inc. (PCVX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Vaxcyte, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Vaxcyte, Inc. (PCVX) Average Enterprise Value

How has PCVX Enterprise Value performed in the past?

The current Enterprise Value of Vaxcyte, Inc. (PCVX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Vaxcyte, Inc. (PCVX) Enterprise Value vs. Peers

How is PCVX’s Enterprise Value compared to its peers?

Vaxcyte, Inc.’s Enterprise Value is greater than Larimar Therapeutics, Inc. (486.93M), greater than Syndax Pharmaceuticals, Inc. (1.52B), greater than Merus N.V. (2.79B), greater than Sutro Biopharma, Inc. (437.33M), greater than Arcellx, Inc. (3.80B), greater than Ventyx Biosciences, Inc. (123.69M), greater than Immunocore Holdings plc (1.64B), greater than DICE Therapeutics, Inc. (2.21B), greater than Nuvalent, Inc. (5.51B), greater than Viridian Therapeutics, Inc. (813.50M), greater than Legend Biotech Corporation (10.04B), greater than Apellis Pharmaceuticals, Inc. (5.11B), greater than Travere Therapeutics, Inc. (1.21B), greater than Akero Therapeutics, Inc. (1.56B), less than BioMarin Pharmaceutical Inc. (16.13B), greater than Liquidia Corporation (568.30M), greater than Bio-Techne Corporation (11.61B),

Build a custom stock screener for Vaxcyte, Inc. (PCVX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Vaxcyte, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Vaxcyte, Inc. (PCVX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Vaxcyte, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.